Aliko Scientific: Its American Subsidiary Will Receive $2M to Close a Dispute
The oncological diagnostic group ALIKO Scientific (Ikonisys SA) announced that its American subsidiary, 100% owned, will receive 2 million dollars under an agreement ending a legal proceeding.
The announcement was published on September 21, 2026 by the company listed on Euronext Growth Paris.
ALIKO Scientific (Ikonisys SA), listed on Euronext Growth Paris under the symbol ALIKO, announced the conclusion of a settlement agreement ending an ongoing dispute involving its American subsidiary 100% owned.
Under the terms of this agreement, it will receive the sum of 2 million US dollars. The company specifies that the legal proceedings relating to this dispute have been closed.
Activities Organized Between the United States and Italy
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Based in Paris, ALIKO Scientific presents itself as the parent company of a group of enterprises dedicated to oncology diagnostics. The group coordinates industrial, financial and research activities through its subsidiaries Ikonisys Inc. (United States) and Hospitex International (Italy).
The subsidiary concerned by the settlement agreement is the American entity of the group.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: FY2024
Key reported figures
Revenue: 1 millions d'euros
Revenue growth: -99,8 %
Net income: -3,2 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
